NCT05776342 Prognostic and Predictive Markers of Treatment Response in Patients With PAC.
| NCT ID | NCT05776342 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Condition | Pancreatic Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,050 participants |
| Start Date | 2003-01-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,050 participants in total. It began in 2003-01-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.
Eligibility Criteria
Inclusion Criteria: * Patient with histologically confirmed pancreatic adenocarcinoma. * Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery * Diagnosis between January 1, 2003, and December 31, 2030. * First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials. * Age ≥ 18 years. * Written informed consent Exclusion Criteria: * Patient under guardianship, curatorship, or judicial protection. * Pregnant or breastfeeding women. * Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator. * Refusal to participate in the study
Contact & Investigator
Angelique VIENOT, MD
PRINCIPAL INVESTIGATOR
CHRU de Besançon - Institut Régional Fédératif du Cancer (IRFC) de Franche-Comté
Frequently Asked Questions
Who can join the NCT05776342 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05776342 currently recruiting?
Yes, NCT05776342 is actively recruiting participants. Contact the research team at regulatory.Affairs@gercor.com.fr for enrollment information.
Where is the NCT05776342 trial being conducted?
This trial is being conducted at Besançon, France, Clichy, France, Créteil, France, Lille, France and 11 additional locations.
Who is sponsoring the NCT05776342 clinical trial?
NCT05776342 is sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group. The principal investigator is Angelique VIENOT, MD at CHRU de Besançon - Institut Régional Fédératif du Cancer (IRFC) de Franche-Comté. The trial plans to enroll 4,050 participants.